The Role of rs2305948 in Determining Vascular Endothelial Growth Factor Levels in Breast Cancer

Abstract

Breast cancer is the most frequent malignancy in women worldwide and is curable in ~70–80% of patients with early-stage, non-metastatic disease. Advanced breast cancer with distant organ metastases is considered incurable with currently available therapies. Vascular endothelial cell growth factor (VEGF) and VEGF receptor 2 (VEGFR2) are closely related to angiogenesis in Breast cancer. Main functions of VEGFR2 include increasing the expression of VEGF and inducing tumor angiogenesis. In addition, VEGF plays a role in promoting vascular endothelial cell division and angiogenesis through VEGFR2 and is also involved in promoting the aggressive growth of tumors. Previous research has revealed that genetic mutations and polymorphisms are closely related to disease susceptibility and can lead to different responses to environmental factors and drugs. Therefore, we conducted this meta-analysis to evaluate the association of rs2305948 with Breast cancer and to obtain a stronger conclusion. Many studies have reported a relationship between the vascular endothelial growth factor receptor 2 single nucleotide polymorphism (SNP) rs2305948 and Breast cancer, but their conclusions have been controversial. A meta-analysis was performed to assess the association between rs2305948 and Breast cancer susceptibility